Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes

(2014) Daniel J. Klionsky et al.   Autophagy

Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models

(2012) Fulvio Chiacchiera et al.   CANCER LETTERS

Chemical genetic discovery of targets and anti-targets for cancer polypharmacology

(2012) Arvin C. Dar et al.   NATURE

Targeted therapy in GIST: in silico modeling for prediction of resistance

(2011) Marco A. Pierotti et al.   Nature Reviews Clinical Oncology

Analysis of Imatinib and Sorafenib Binding to p38α Compared with c-Abl and b-Raf Provides Structural Insights for Understanding the Selectivity of Inhibitors Targeting the DFG-Out Form of Protein Kinases

(2010) Haridasan V. Namboodiri et al.   BIOCHEMISTRY

Insights into MAPK p38α DFG flip mechanism by accelerated molecular dynamics

(2010) Federico Filomia et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The AMPK-FoxO3A axis as a target for cancer treatment

(2010) Fulvio Chiacchiera et al.   CELL CYCLE

p38α Is Required for Ovarian Cancer Cell Metabolism and Survival

(2010) Antonio Matrone et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma

(2010) Bernhard Gillissen et al.   JOURNAL OF CELL BIOLOGY

Evolving Treatment of Advanced Colon Cancer

(2009) Neil H. Segal et al.   Annual Review of Medicine

Inhibition of p38α unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism

(2009) Fulvio Chiacchiera et al.   Autophagy

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

p38α blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1α- to FoxO-dependent transcription

(2009) F Chiacchiera et al.   CELL DEATH AND DIFFERENTIATION

The PKB/AKT Pathway in Cancer

(2009) Amancio Carnero   CURRENT PHARMACEUTICAL DESIGN

Signal-dependent regulation of gene expression as a target for cancer treatment: Inhibiting p38α in colorectal tumors

(2008) Fulvio Chiacchiera et al.   CANCER LETTERS

Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States

(2008) Irina Kufareva et al.   JOURNAL OF MEDICINAL CHEMISTRY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM

(2008) J A Wickenden et al.   ONCOGENE

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

(2008) L. Dal Lago et al.   ONCOLOGIST